Theravance Biopharma TBPH Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Licensing And Milestone | $32.5M— | —— | —— | —— | |
| Yupelri Monotherapy | $93.31M+11.7% | $83.52M+8.0% | $77.34M+9.5% | $70.65M+24.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Theravance Biopharma break its business down?
- Theravance Biopharma (TBPH) reports revenue by product across 2 parts — Licensing And Milestone and Yupelri Monotherapy. Each is extracted from the segment footnotes and tracked over time.
- Where does Theravance Biopharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Theravance Biopharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
